Hit enter to search or ESC to close
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
AI-POWR™
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
Hepion Tackles NASH in P2 with Cyclophilin Inhibitor [Breaking Biotech]
By
Hepion
October 11, 2020
December 2nd, 2020
Media Placements
,
Videos
No Comments
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
July 23, 2021
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
July 13, 2021
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
June 25, 2021
Share
Tweet
Share
Pin
About
Company Overview
Executive Team
Cyclophilin Expertise
Board of Directors
Scientific Advisory Board
Partnering
Liver Disease
Overview
Non-alcoholic Steatohepatitis (NASH)
Hepatocellular Carcinoma (HCC)
Viral Hepatitis
AI-POWR™
Pipeline
Overview
CRV431
Therapeutic Strategy
Clinical Trials
Publications
Newsroom
Investors
Investor Overview
Press Releases
Events
Presentations
Company Information
Stock Information
SEC Filings
Corporate Governance
Contact
Contact Us
Careers
